Two biosimilars have been approved for retinal indications. What conclusions were drawn from the phase 3 studies that preceded their approval? Yasha Modi, MD, is joined by Kyle Kovacs, MD, and Priya Vakharia, MD, to review the ins and outs of biosimilarity, discuss the findings of two recent papers, and consider how use of biosimilars might affect future clinical practice in the United States.